Hyperacidity, GERD, and ulcers:
Indications for: LIBRAX
Adjunct in peptic ulcer. Irritable bowel syndrome. Acute enterocolitis.
Individualize. Usually 1–2 caps 3–4 times daily before meals and at bedtime. Elderly or debilitated: max 2 caps daily initially, then may increase gradually.
Glaucoma. GI or GU obstruction.
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
Risks from concomitant use with opioids; see Interactions. Monitor for paradoxical reactions. Depression. Suicidal tendencies (monitor). Hepatic or renal impairment. Obtain LFTs and blood counts periodically in prolonged use. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Drug or alcohol abusers. Write ℞ for smallest practical amount. Elderly. Debilitated. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: monitor infants.
Benzodiazepine + anticholinergic.
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Additive CNS depressant effects with alcohol or other CNS depressants. Concomitant other psychotropic agents (eg, MAOIs, phenothiazines): not recommended. Increased constipation with concomitant other spasmolytic agents and/or a low residue diet. May rarely interfere with oral anticoagulants.
Drowsiness, anticholinergic effects (eg, dry mouth, blurred vision, urinary hesitancy, constipation), ataxia, confusion; rare: jaundice, blood dyscrasias, withdrawal reactions.
Renal. Half-life: 24–48 hours (chlordiazepoxide).
Generic Drug Availability: